Cancer Biomarkers · 2015 · 28 citations · 0 references
Life SciencesMolecular BiologyOncologyGene ExpressionMolecular OncologyTranscriptomicsCancer BiomarkersCancer Molecular DiagnosticsCancer TranscriptomicsIsoform Expression AnalysisMetastatic Breast CancerMolecular Tumor ProfilingBreast Cancer Molecular SubtypesDifferential Transcript ExpressionHormone Biomarkers In CancerIsoform Differential ExpressionIsoform QuantificationMessenger Rna Biomarker AnalysisQuantitative Pcr DetectionReceptor Splice Variants
BACKGROUND: The mature human insulin receptor (INSR) has two isoforms: The A isoform and the B isoform. INSR upregulation has been suggested to play a role in cancer. OBJECTIVE: To establish quantitative PCR method for INSR transcript variants and examine their differential expression as a diagnostic tumor marker in breast cancer. METHODS: The differential expression of IR-A and IR-B were evaluated by TaqMan qRT-PCR assay in the commercially available Breast Cancer Disease cDNA and Cancer Survey cDNA arrays. RESULTS: The mRNA expression levels of IR-A was statistically significantly higher in breast cancer when compared to normal breast tissue while IR-B mRNA expression was down regulated significantly in breast cancer. Stratification of patients into groups according to metastatic stages indicated statistically significantly higher levels of IR-A mRNA in clinical stage (CS)-IV, and lower IR-B levels in CS-IIA, CS-IIIB and CS-IIIC. However, IR-A:IR-B ratio showed a statistically significant increase in all stages. Cancer Survey cDNA array demonstrated lower levels of IR-B mRNA in breast adenocarcinoma, liver carcinoma and lung carcinoma only while IR-A expression was significantly altered in kidney carcinoma without any significant differences in IR-A:IR-B ratios. CONCLUSIONS: The results demonstrate an increased IR-A:IR-B ratio in all clinical stages of breast cancer. Thus, IR-A:IR-B ratio may have a diagnostic biomarker utility in breast cancer.